Can Wegovy Reduce Cholesterol? What the Clinical Trials Found

What the STEP trials recorded about cholesterol and triglycerides

The STEP 1 trial, published in the New England Journal of Medicine, randomised 1,961 adults with obesity to either semaglutide 2.4mg weekly or placebo over 68 weeks. Alongside the headline weight finding (an average reduction of around 15% of body weight) participants receiving semaglutide showed statistically significant improvements in fasting lipids. LDL cholesterol fell. Triglycerides dropped by more than in the placebo group. HDL, the so-called protective cholesterol, edged upward.

These are not dramatic, stand-alone cholesterol drugs results. They sit within a cluster of cardiovascular risk improvements (blood pressure, waist circumference, inflammatory markers) that tend to move together when meaningful weight loss occurs. If you want a fuller answer to the question of whether Wegovy helps with cholesterol, that page sets out what the evidence shows across the different lipid markers. The honest framing is that Wegovy improves cholesterol as part of a wider metabolic shift, not in isolation from everything else changing at the same time.

The SELECT cardiovascular outcomes trial, which enrolled over 17,000 adults with established cardiovascular disease but without diabetes, confirmed that semaglutide 2.4mg reduced the risk of major cardiovascular events by 20% versus placebo over roughly three years. Improved lipid profiles were among the contributing mechanisms discussed by investigators.

Why weight loss and semaglutide both play a part

There is a common assumption that any cholesterol improvement on Wegovy is simply the arithmetic of losing weight. That is partly true and worth acknowledging plainly. Losing 10–15% of body weight reliably lowers triglycerides and LDL in most people, regardless of how the weight was lost. So some of what the STEP trials recorded would happen with an equivalent amount of weight lost through diet alone.

But GLP-1 receptor agonists like semaglutide also appear to have direct effects on lipid handling in the liver, independent of weight change. Research published in peer-reviewed journals suggests semaglutide reduces hepatic fat accumulation, which in turn influences how the liver processes and exports cholesterol-carrying particles. This is one reason the MHRA approved Wegovy in July 2026 for MASH, a form of fatty liver disease, alongside its weight-management and cardiovascular licences.

If you want to understand the broader picture of how semaglutide drives weight reduction, that mechanism page covers the appetite and gastric-emptying effects in more detail. The short version: slower stomach emptying and reduced appetite lead to lower calorie intake, and that metabolic change ripples into lipid profiles over weeks to months.

Who is likely to see cholesterol benefits, and who should manage expectations

People with elevated triglycerides at baseline tend to see the most pronounced reductions. Those with modestly raised LDL in the context of overweight or obesity often see a meaningful drop. For someone whose cholesterol is already well-controlled, perhaps through statins, Wegovy will not replace that medication and is not prescribed with that goal.

The NHS medicines information for semaglutide notes that Wegovy is licensed for weight management in adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition. Cardiovascular disease, high blood pressure and dyslipidaemia all count as qualifying conditions. So for many people asking whether Wegovy can reduce cholesterol, the situation is that their raised cholesterol may itself be part of what makes them clinically suitable for treatment.

None of this means the medicine works the same way for everyone, and a prescriber will look at your full picture, including existing cholesterol-lowering medication, before making a recommendation. If you are exploring what Wegovy costs in the UK, that page sets out what is typically included in a private prescription service. For those curious about the precise effects of semaglutide on lipid markers, the detailed breakdown of Wegovy's effect on cholesterol covers the mechanisms and numbers more closely.

Monitoring and the prescriber's role during treatment

Cholesterol is not a static figure, and it is not the only marker that shifts during treatment. A good prescriber tracks your progress over the months of treatment, not just at the start. At nume, every repeat order goes through a fresh clinical review rather than auto-renewing, which means your evolving health picture, including any cholesterol or blood-pressure changes, informs each decision.

If your GP is already managing your cholesterol with medication, it is worth telling them you are starting or considering Wegovy so they can keep both pictures in view. The NHS advises patients to share their full medication list with any prescriber, and that is good practice here too. People starting semaglutide for the first time often focus on nausea in the early weeks; the slower-moving changes to lipid profiles and cardiovascular markers tend to emerge over months rather than days. That timeline is worth knowing in advance. Reporting any unexpected symptoms through the MHRA Yellow Card scheme remains open to anyone on treatment.

If you are considering Wegovy and want to understand whether it is clinically appropriate for your situation, including your cardiovascular risk profile, check your eligibility with our prescribers. The consultation is free, and a GPhC-registered Independent Prescriber reviews your answers the same day.